Chronic Hepatitis

Monotherapy with bulevirtide among patients with compensated hepatitis delta was safe and well tolerated, according to a presentation at the International Liver Congress.

Tenofovir reduced the severity of COVID-19 infection among patients with chronic hepatitis B, according to a presentation at The Digital International Liver Congress.

Ravidasvir in addition to sofosbuvir was safe and effective in the treatment of patients with chronic hepatitis C virus, according to research published in The Lancet Gastroenterology and Hepatology.

More patients underwent hepatitis C virus screening when there was a reduced effort in attaining a laboratory order compared with patients who had to request screening on their own, according to research published in BMJ.

A one-time, universal screening for chronic hepatitis B infection could prevent 23,000 additional deaths from chronic HBV-related liver disease and save almost $600 million, according to a study in Clinical Infectious Diseases.

Brii Biosciences, Vir Biotechnology and VBI Vaccines announced the first patient dosed in a phase 2 trial evaluating combination therapy for the treatment of patients with chronic hepatitis B infection, according to a press release.

Healio Gastroenterology presents the following reports on the most recent research in hepatology.

Despite a global initiative to reduce hepatitis B mortality, few of the countries with the highest burden are on track to meet elimination targets, according to research presented at the Liver Meeting Digital Experience.

For patients with chronic hepatitis B, aspirin therapy correlated with a reduced risk for hepatocellular carcinoma, according to a presenter at The Liver Meeting Digital Experience.

It is feasible for patients with negative HBV e-antigen chronic hepatitis B to discontinue nucleos(t)ide analogues therapy with low quantitative hepatitis B surface antigen levels, per a presentation at The Liver Meeting Digital Experience.